Literature DB >> 10798161

Pneumonia due to unusual organisms in children.

K Chugh1.   

Abstract

Generally antimicrobials for treatment of pneumonia are chosen to target the usual bacterial etiological agents. Such regimens are unable to cure patients of pneumonia caused by 'unusual organisms' mycoplasma, chlamydia, Pneumocystis carinii and Legionella pneumophilus). Thus, there is a need to anticipate their presence in appropriate cases and to plan the initial antimicrobial therapy accordingly. Studies in Europe as well as India have shown that such infections form a fairly substantial percentage of community acquired pneumonia in children. Mycoplasma pneumoniae and Chlamydia pneumoniae are common in school age children while Chlamydia trachomatis occurs in early infancy. Pneumocystis carinii is an important pathogen in immunocompromised children. Routine laboratory tests and radiological features are not specific enough to give accurate diagnosis of these infections for which one has to depend on sophisticated culture techniques, immunological tests for the antigens or antibodies and polymerase chain reaction. Mycoplasma, chlamydia and legionella infections respond to macrolide antibiotics and for pneumocystis infections, trimethoprim-sulfamethaxozole or pentamidine is the drug of choice. Overall prognosis with appropriate treatment is good except for P. carinii infection in immunocompromised host which carries a high mortality and recurrence rate.

Entities:  

Mesh:

Year:  1999        PMID: 10798161     DOI: 10.1007/bf02723871

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  28 in total

1.  Acute lower-respiratory-tract infection associated with chlamydial TWAR antibody in Filipino children.

Authors:  P Saikku; P Ruutu; M Leinonen; J Panelius; T E Tupasi; J T Grayston
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

2.  Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.

Authors:  D L Hahn; R W Dodge; R Golubjatnikov
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

3.  The unusual severity of Mycoplasmal pneumonia in children with sickle-cell disease.

Authors:  S T Shulman; J Bartlett; W A Clyde; E M Ayoub
Journal:  N Engl J Med       Date:  1972-07-27       Impact factor: 91.245

4.  Comparison of Gen-Probe commercial kit and culture technique for the diagnosis of Mycoplasma pneumoniae infection.

Authors:  R Dular; R Kajioka; S Kasatiya
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

5.  Laboratory diagnosis of Mycoplasma pneumoniae infection. 1. Direct detection of antigen in respiratory exudates by enzyme immunoassay.

Authors:  T W Kok; G Varkanis; B P Marmion; J Martin; A Esterman
Journal:  Epidemiol Infect       Date:  1988-12       Impact factor: 2.451

6.  Simplified microimmunofluorescence test with trachoma-lymphogranuloma venereum (Chlamydia trachomatis) antigens for use as a screening test for antibody.

Authors:  S P Wang; J T Grayston; E R Alexander; K K Holmes
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

7.  Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age.

Authors:  M A Tipple; M O Beem; E M Saxon
Journal:  Pediatrics       Date:  1979-02       Impact factor: 7.124

8.  The association of Chlamydia pneumoniae infection and reactive airway disease in children.

Authors:  U Emre; P M Roblin; M Gelling; W Dumornay; M Rao; M R Hammerschlag; J Schachter
Journal:  Arch Pediatr Adolesc Med       Date:  1994-07

9.  Neonatal Legionnaires' disease. Histopathological findings in an autopsied neonate.

Authors:  H Horie; H Kawakami; K Minoshima; T Kamohara; T Nakamura; H Kuroki; A Nakamura
Journal:  Acta Pathol Jpn       Date:  1992-06

10.  Prospective study of perinatal transmission of Chlamydia trachomatis.

Authors:  J Schachter; M Grossman; R L Sweet; J Holt; C Jordan; E Bishop
Journal:  JAMA       Date:  1986-06-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.